Metabolic diseases represent a diverse clinical spectrum – from highly prevalent conditions such as type 1 and type 2 diabetes, obesity, and metabolic complications, to rarer metabolic and renal manifestations such as Alagille syndrome, complement 3 glomerulopathy, as well as more common renal conditions such as chronic kidney disease.
With incretin-based therapies advancing rapidly, oral agents expanding across options, extended dosing internals and now approaches emerging across both common and rare disease areas, the landscape is evolving.
As clinical guidelines and real-world practice patterns shift in response, robust multi-stakeholder real-world evidence is essential for understanding disease progression, guiding clinical strategies, supporting market access, and strengthening confidence in treatment outcomes.
Adelphi Real World’s Metabolic Disease Specific Programmes (DSPs) are designed to deliver precisely this intelligence.
Our Metabolic DSPs engage specialist physicians from primary and secondary care and people with lived experience to generate evidence grounded in real-world clinical practice:
Metabolic Assessment & Monitoring Approaches
Understand how specialist physicians diagnose, stratify risk, and monitor metabolic disease—capturing real-world clinical evaluations, biomarker use, complication screening, and evaluation of disease severity in routine clinical settings.
Treatment Selection & Therapeutic Strategies
Benchmark real-world therapy patterns: how clinicians select, sequence, and optimise treatments across the metabolic spectrum – from lifestyle and established pharmacotherapies to second generation incretin-based agents, longer-acting therapies, and emerging oral options. Capture the clinical rationale supporting treatment choices, switching behaviour and early adoption of new therapies across the metabolic disease spectrum.
Clinical Outcomes & Disease Control
Assess real-world effectiveness, including metabolic control, complication prevention, disease stabilisation, cardiovascular protection, and functional improvement across diverse patient populations and healthcare systems.
Patient Burden & Disease Management
Explore the patient perspective: metabolic symptom burden, impact of complications, treatment tolerability, adherence challenges, impact on work productivity, and quality-of-life. Assessment of how evolving care models such as telemedicine and remote prescribing influence patient experience and engagement.
Therapeutic Gaps & Emerging Opportunities
Identify unmet treatment needs, areas where current management is inefficient, and opportunities for next-generation therapeutic innovation.
Metabolic Disease Specific Programmes (DSPs) Portfolio
Click on the hexagons to expand.
Why Partner With Adelphi?
Metabolic Disease Expertise
Over 30 years of specialisation across endocrine, metabolic, and metabolic-renal disease domains.
Pan-Speciality Clinician Networks
Access to endocrinologists, diabetologists, weight-management specialists, hepatologists, gastroenterologists, nephrologists, and metabolic specialists across diverse care settings.
Comprehensive Condition Coverage
Evidence spanning high-prevalence metabolic disease and rare metabolic-renal manifestations.
Patient-Informed Intelligence
Evidence capturing real-world lived experience and disease burden.
Integrated Strategic Evidence
Intelligence supporting clinical development, scientific communication, reimbursement discussions and healthcare engagement.
Geographies Covered By DSPs In Metabolic Diseases
Who We Engage With
We partner with endocrinology and metabolic centres, specialist metabolic and weight‑management clinics, patient organisations, and wider healthcare communities. Through these collaborations, we generate high‑quality real‑world evidence that deepens understanding of metabolic diseases and drives better outcomes for patients worldwide.
Let’s Begin
- Schedule a Consultation: Connect with our metabolic disease and methodology specialists to explore how our real-world evidence can support your evidence needs.
- Explore Possibilities: Want to learn more about our global reach, condition expertise, or real-world methodologies? Contact us for tailored insights.
Strengthen your rare disease research with Adelphi Real World’s integrated DSP solutions. Let’s collaborate to deepen clinical understanding, drive therapeutic innovation, and ultimately improve outcomes for rare disease patients worldwide.
Contact us today using the form below.
Conferences Attending
Observational Research